Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, has announced an upcoming investor webcast. The event, scheduled for Tuesday, September 24, 2024, at 8:30 a.m. ET, will provide an update on the company's Duchenne muscular dystrophy (DMD) program.
The webcast will include the latest regulatory updates following Capricor's recent meetings with the U.S. Food and Drug Administration (FDA). Investors can participate via conference call or webcast, with dial-in numbers provided for both domestic and international callers. A replay of the webcast will be available on the company's website after the live broadcast.
Capricor Therapeutics (NASDAQ: CAPR), una compagnia biotecnologica focalizzata nello sviluppo di terapie basate su cellule ed esosomi per malattie rare, ha annunciato un prossimo webcast per gli investitori. L'evento, previsto per martedì 24 settembre 2024, alle 8:30 ET, fornirà aggiornamenti sul programma della compagnia relativo alla distrofia muscolare di Duchenne (DMD).
Il webcast includerà gli ultimi aggiornamenti normativi in seguito agli incontri recenti di Capricor con la Food and Drug Administration (FDA) degli Stati Uniti. Gli investitori possono partecipare tramite conferenza telefonica o webcast, con numeri di accesso forniti per i chiamanti sia nazionali che internazionali. Una registrazione del webcast sarà disponibile sul sito web della compagnia dopo la trasmissione dal vivo.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en el desarrollo de terapias basadas en células y exosomas para enfermedades raras, ha anunciado una próxima transmisión web para inversores. El evento, programado para el martes 24 de septiembre de 2024, a las 8:30 a.m. ET, proporcionará una actualización sobre el programa de la compañía relacionado con la distrofia muscular de Duchenne (DMD).
La transmisión incluirá las últimas actualizaciones regulatorias tras las reuniones recientes de Capricor con la Administración de Alimentos y Medicamentos de EE. UU. (FDA). Los inversores pueden participar a través de conferencia telefónica o webcast, con números de acceso proporcionados para los llamantes nacionales e internacionales. Una repetición de la transmisión estará disponible en el sitio web de la empresa después de la transmisión en vivo.
Capricor Therapeutics (NASDAQ: CAPR)는 희귀 질환을 위한 세포 및 외소포 기반 치료제를 개발하는 생명공학 회사로, 투자자 웹캐스트를 곧 개최한다고 발표했습니다. 이 행사는 2024년 9월 24일 화요일 오전 8시 30분 ET에 예정되어 있으며, 회사의 뒤신형 근이 영양 장애(DMD) 프로그램에 대한 업데이트를 제공합니다.
웹캐스트에는 Capricor의 최근 미국 식품의약국(FDA)와의 회의에 따른 최신 규제 정보가 포함될 것입니다. 투자자들은 전화회의 또는 웹캐스트를 통해 참여할 수 있으며, 국내외 발신자를 위한 접속 번호가 제공됩니다. 라이브 방송 후 회사 웹사이트에서 웹캐스트의 재생이 가능합니다.
Capricor Therapeutics (NASDAQ: CAPR), une entreprise de biotechnologie axée sur le développement de thérapies basées sur des cellules et des exosomes pour les maladies rares, a annoncé un prochain webinaire pour investisseurs. L'événement, prévu pour le mardi 24 septembre 2024 à 8h30 ET, fournira une mise à jour sur le programme de l'entreprise concernant la dystrophie musculaire de Duchenne (DMD).
Le webinaire comprendra les dernières mises à jour réglementaires suite aux réunions récentes de Capricor avec la Food and Drug Administration (FDA) des États-Unis. Les investisseurs peuvent participer par conférence téléphonique ou webinaire, avec des numéros de connexion fournis pour les appelants nationaux et internationaux. Un replay du webinaire sera disponible sur le site web de l'entreprise après la diffusion en direct.
Capricor Therapeutics (NASDAQ: CAPR), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von zell- und exosombasierten Therapien für seltene Krankheiten konzentriert, hat ein bevorstehendes Investor-Webcast angekündigt. Die Veranstaltung, die für Dienstag, den 24. September 2024, um 8:30 Uhr ET geplant ist, wird ein Update zum Duchenne-Muskeldystrophie-Programm (DMD) des Unternehmens bieten.
Das Webcast wird die neuesten behördlichen Aktualisierungen nach den jüngsten Treffen von Capricor mit der U.S. Food and Drug Administration (FDA) enthalten. Investoren können über eine Telefonkonferenz oder einen Webcast teilnehmen, wobei Zugangsnummern für nationale und internationale Anrufer bereitgestellt werden. Eine Aufzeichnung des Webcasts wird nach der Live-Übertragung auf der Website des Unternehmens verfügbar sein.
- Capricor is providing an update on its Duchenne muscular dystrophy program, indicating ongoing development in this area
- The company has recently met with the FDA, suggesting progress in regulatory discussions
- None.
Investor Webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company’s recent meetings with the U.S. Food and Drug Administration (FDA).
Webcast Details
Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-717-1738 (domestic/toll-free) or 1-646-307-1865 (international) and reference the conference ID: 62574. Participants can use guest dial-in numbers above and be answered by an operator or click here for instant telephone access. To participate via webcast, please click here to view the slides. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 8, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
When is Capricor Therapeutics (CAPR) hosting its investor webcast for the DMD program update?
What will be discussed in Capricor Therapeutics' (CAPR) upcoming webcast?
How can investors participate in Capricor Therapeutics' (CAPR) September 24, 2024 webcast?
Will there be a replay available for Capricor Therapeutics' (CAPR) September 24, 2024 webcast?
